Zydus Lifesciences company profile
Company profile
Zydus Lifesciences has 29,980 employees and is headquartered in Ahmedabad, India.
Glucon D, Complan, Nycil, Everyuth, Nutralite and RiteBite Max Protein are among the consumer brands through which Zydus Lifesciences sells products in India and abroad, alongside a pharmaceutical business that covers active pharmaceutical ingredients, generics, branded generics, specialty formulations, biosimilars and vaccines. The company also develops biological products for oncology, autoimmune disorders, nephrology, rheumatology, hepatology and infectious diseases, and runs clinical trials for new chemical entities, biologics and vaccines. It reports across three segments: Pharmaceuticals, Consumer Products and Medical Technologies, with markets in India, the United States and Europe.
In the fiscal year ended March 2026, revenue rose 16.8% to INR 271.5 billion and net profit reached INR 50.4 billion. The company employed 29,980 people. Founded in 1952, it was formerly known as Cadila Healthcare Limited until it changed its name in February 2022, and it is headquartered in Ahmedabad, India. It is a subsidiary of Zydus Family Trust.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- India
- Headquarters
- Zydus Corporate Park, 382481, Ahmedabad
- Employees
- 29,980
- Chief executive
- Sharvil Patel
- Founded
- 1952
- Fiscal year
- April - March
- Listing
- ZYDUSLIFE · NSE
- Currency
- INR
- ISIN
- INE010B01027
- Website
- zyduslife.com
Zydus Lifesciences and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Zydus LifesciencesZYDUSLIFE | India | $12.92B | 29,980 | 17.2% | 28.7 |
| CiplaCIPLA | India | $12.34B | 31,369 | 13.0% | 39.5 |
| Zhejiang NHU002001 | China | $11.61B | 11,508 | 33.8% | 10.6 |
| Laurus LabsLAURUSLABS | India | $14.13B | 7,059 | 24.1% | 97.8 |
| Yunnan Baiyao Group000538 | China | $15.07B | 9,286 | 11.2% | 19.4 |
| PharmaEssentia6446 | Taiwan | $15.94B | 131 | 38.4% | 74.1 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
